Pieris Pharmaceuticals Gmbh

Daiichi Sankyo Company, Limited

Sakiko Takahashi

Tohru Takahashi

Ryuji Hashimoto

Christine Rothe

Andrea Allersdorfer

Marlon Hinner

Alexander Wiedenmann

Gabriele Matschiner

Rachida Siham Bel Aiba

Bradley Lunde

Kazufumi Kubota

Mamoru Otoyo

Mitsuhiro Makino

Tsuyoshi Shinozuka

Yuki Domon

Yutaka Kitano

The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions and combinations comprising one or more of such muteins.

Proteins specific for calcitonin gene-related peptide

It is intended to provide a therapeutic agent and/or a preventive agent for a respiratory disease or a therapeutic agent and/or a preventive agent for a sodium channel associated disease. The present invention provides a pharmaceutical comprising a compound represented by the following formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: 

Drugs for treating respiratory diseases

Growing community of inventors

Tokyo, Japan

Sakiko Takahashi